New York, NY -- (SBWIRE) -- 01/02/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: BlackRock Debt Strategies Fund, Inc (NYSE:DSU), Peregrine Pharmaceuticals (NASDAQ:PPHM), Cell Therapeutics Inc (NASDAQ:CTIC) ,Revolution Lighting Technologies Inc (NASDAQ:RVLT)
BlackRock Debt Strategies Fund, Inc (NYSE:DSU) showed a volume of 1.68 million shares by the end of last trade whereas the average volume of the stock remained 667,124.00 shares. The stock opened the session at $3.99but then moved to $3.99. BlackRock Debt Strategies Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The Fund seeks to provide current income by investing primarily in a diversified portfolio of the United States companies’ debt instruments, including corporate loans, that are rated in the lower rating categories of the established rating services (Baa or lower by Moody’s or BBB or lower by S&P’s) or unrated debt instruments of comparable quality.
Is DSU a Solid Investment at These Levels? Read This Report For Details
Peregrine Pharmaceuticals (NASDAQ:PPHM) opened the session at $1.42 and closed the session at $1.39. The stock showed a negative performance of -2.11% in previous trading session. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer.
Has PPHM Found The Bottom And Ready To Gain Momentum? Find Out Here
Cell Therapeutics Inc (NASDAQ:CTIC) opened the session at $1.94 and closed the session at $1.91. The stock showed a negative performance of -0.52% in previous trading session. The beta of the stock remained 5.59. Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL),
Why Should Investors Buy CTIC After the Recent Fall? Just Go Here and Find Out
Revolution Lighting Technologies Inc (NASDAQ:RVLT) the stock advanced 9.08% and finished the session at $3.42. Traded with volume of 1.62 million shares in the prior session and the average volume of the stock remained 615,242.00 shares. The beta of the stock remained 2.15. Revolution Lighting Technologies Inc. designs, manufacture, market and sells commercial grade, light emitting diode (LED) replacement light bulbs and LED-based signage, channel letter and contour lighting products. The Company sells these products under the Seesmart, Array Lighting and Lumificient brand names. The Company operates in two segments: LED replacement lamps and fixtures and LED signage and lighting strips. On December 20, 2012,
Will RVLT Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)